PCN22 COST-EFFECTIVENESS (CE) OF THE PREVENTION OF ORAL MUCOSITIS (OM) WITH KEPIVANCE® (PALIFERMIN) IN PATIENTS UNDERGOING MYELOABLATIVE THERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN SPAIN
Nov 1, 2006, 00:00 AM
10.1016/S1098-3015(10)63452-3
https://www.valueinhealthjournal.com/article/S1098-3015(10)63452-3/fulltext
Section Title :
Section Order :
302
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)63452-3&doi=10.1016/S1098-3015(10)63452-3